Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction

被引:12
作者
Dahhan, Taghride [1 ]
Balkenende, Eva [2 ]
van Wely, Madelon [1 ]
Linn, Sabine [3 ]
Goddijn, Mariette [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1105 AZ Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Dept Med Oncol, Amsterdam, Netherlands
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2013年 / 11期
关键词
FERTILITY PRESERVATION; OVARIAN STIMULATION; YOUNG-WOMEN;
D O I
10.1002/14651858.CD010240.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cryopreservation of oocytes or embryos preceded by controlled ovarian stimulation (COS) can increase the chance of future pregnancy in women with breast cancer who risk therapy-induced ovarian failure. In women with estrogen-receptor (ER) positive breast cancer, alternative COS protocols with tamoxifen or letrozole are being used to theoretically inhibit breast cancer growth during COS. Objectives To assess the effects of tamoxifen or letrozole, in addition to standard COS protocols, on the breast cancer free interval in premenopausal women with ER positive breast cancer who undergo COS for embryo or oocyte cryopreservation. Search methods We searched the Ovid Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, Ovid PsycINFO, and EBSCOhost CINAHL. We applied no limitations in year of publication or language. In addition, we searched trial registers for ongoing and registered trials, conference abstracts, and sources of grey literature. The search was conducted in January 2013. Selection criteria Randomised trials comparing different COS protocols in women with breast cancer were eligible for inclusion. Data collection and analysis Two review authors independently scanned the titles, abstracts, or both sections according to Cochrane guidelines. If data to include were provided, data extraction would have been independently performed by two review authors by using forms designed according to Cochrane guidelines. Main results No randomised controlled trials were found that met the inclusion criteria. Authors' conclusions COS schedules with the additional use of tamoxifen or letrozole are commonly chosen as an alternative regimen in young women with ER positive breast cancer who undergo COS for oocyte or embryo cryopreservation. No randomised controlled trials support the idea that these alternative COS schedules are superior to standard COS.
引用
收藏
页数:20
相关论文
共 20 条
[1]   Safety of fertility preservation by ovarian stimulation with letrozole and Gonadotropins in patients with breast cancer: A prospective controlled study [J].
Azim, Amr A. ;
Costantini-Ferrando, Maria ;
Oktay, Kutluk .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2630-2635
[3]  
Goodwin PJ, 2005, NEW ENGL J MED, V353, P1418
[4]  
HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
[5]   Quantifying heterogeneity in a meta-analysis [J].
Higgins, JPT ;
Thompson, SG .
STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558
[6]   Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales [J].
Higgins, Julian P. T. ;
White, Ian R. ;
Anzures-Cabrera, Judith .
STATISTICS IN MEDICINE, 2008, 27 (29) :6072-6092
[7]   Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system [J].
Hudis, Clifford A. ;
Barlow, William E. ;
Costantino, Joseph P. ;
Gray, Robert J. ;
Pritchard, Kathleen I. ;
Chapman, Judith-Anne W. ;
Sparano, Joseph A. ;
Hunsberger, Sally ;
Enos, Rebecca A. ;
Gelber, Richard D. ;
Zujewski, Jo Anne .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :2127-2132
[8]   New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer [J].
Jordan, V. Craig .
STEROIDS, 2007, 72 (13) :829-842
[9]   Tamoxifen: A most unlikely pioneering medicine [J].
Jordan, VC .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) :205-213
[10]  
Kovács P, 2008, EUR J GYNAECOL ONCOL, V29, P425